Lexicon Pharmaceuticals (LXRX) Depreciation & Amortization (CF) (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $110000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 37.5% year-over-year to $110000.0 in Q1 2026; TTM through Mar 2026 was $555000.0, a 1.94% decrease from a year earlier, with the FY2025 full-year figure at $621000.0, up 16.29% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $110000.0, down from $118000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for LXRX reached as high as $176000.0 in Q1 2025 and fell as low as $103000.0 in Q4 2022.
• Historically, Depreciation & Amortization (CF) has averaged $132117.6 across 5 years, with a median of $126000.0 in 2024.
• Across the five-year window, Depreciation & Amortization (CF) surged 194.59% in 2022 and plunged 37.5% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $103000.0 in 2022, then surged by 42.72% to $147000.0 in 2023, then slipped by 14.97% to $125000.0 in 2024, then retreated by 5.6% to $118000.0 in 2025, then declined by 6.78% to $110000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $110000.0 in Q1 2026, $118000.0 in Q4 2025, and $151000.0 in Q3 2025.